ArticleAntimicrobial agents and chemotherapy2004
Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Synthesis, Biocidal and Antibiofilm Activities of New Isatin-Quinoline Conjugates against Multidrug-Resistant Bacterial Pathogens along with Their In Silico Screening.Antibiotics (Basel, Switzerland) · 2022Article
- Cyclofaulknamycin with the Rare Amino Acid D-capreomycidine Isolated from a Well-CharacterizedMicroorganisms · 2021Article
- Antibacterial activities of the extracts, fractions and isolated compounds from Canarium patentinervium Miq. against bacterial clinical isolates.BMC complementary medicine and therapies · 2020Article
- Molecular identification and antibacterial properties of an ericoid associated mycorrhizal fungus.BMC microbiology · 2019Article
- Antibacterial Effect ofFrontiers in microbiology · 2018Article
- Novel vancomycin-peptide conjugate as potent antibacterial agent against vancomycin-resistantInfection and drug resistance · 2018Article
- Diversity, Phylogeny, anticancer and antimicrobial potential of fungal endophytes associated with Monarda citriodora L.BMC microbiology · 2017Article
- Article
- Enduracididine, a rare amino acid component of peptide antibiotics: Natural products and synthesis.Beilstein journal of organic chemistry · 2016Review
- The evolving role of chemical synthesis in antibacterial drug discovery.Angewandte Chemie (International ed. in English) · 2014Review
- Alternative strategies for proof-of-principle studies of antibacterial agents.Antimicrobial agents and chemotherapy · 2014Review
- Cytotoxic and antimicrobial activities of endophytic fungi isolated from Bacopa monnieri (L.) Pennell (Scrophulariaceae).BMC complementary and alternative medicine · 2014Article
- Article
- Antistaphylococcal activity of bacteriophage derived chimeric protein P128.BMC microbiology · 2012Article
- Synthetic studies toward the mannopeptimycins: synthesis of orthogonally protected beta-hydroxyenduracididines.Organic letters · 2010Article
- Antibacterial cyclic D,L-alpha-glycopeptides.Chemical communications (Cambridge, England) · 2009Article
- Synthesis of aza-analogues of the glycosylated tyrosine portion of mannopeptimycin-E.The Journal of organic chemistry · 2007Article
- Biosynthetic pathway for mannopeptimycins, lipoglycopeptide antibiotics active against drug-resistant gram-positive pathogens.Antimicrobial agents and chemotherapy · 2006Article
- Synthetic studies toward mannopeptimycin-E: synthesis of the O-linked tyrosine 1,4-alpha,alpha-manno,manno-pyranosyl pyranoside.Organic letters · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AC98-6446 is a novel semisynthetic cyclic glycopeptide antibiotic related to the natural product mannopeptimycin alpha (AC98-1). In the present study the activity of AC98-6446 was evaluated against a variety of recent clinical gram-positive pathogens including multiply resistant strains. AC98-6446 demonstrated similar potent activities against methicillin-susceptible and methicillin-resistant staphylococci and glycopeptide-intermediate staphylococcal isolates (MICs at which 90% of isolates are inhibited [MIC(90)s], 0.03 to 0.06 microg/ml). AC98-6446 also demonstrated good activities against both vancomycin-resistant and -susceptible strains of enterococci (MIC(90)s, 0.12 and 0.25 microg/ml, respectively) as well as against streptococcal strains (MIC(90)s, <or= 0.008 to 0.03 microg/ml). AC98-6446 demonstrated bactericidal activity in terms of the reduction in the viable counts (>3 log(10) CFU/ml) of staphylococcal and streptococcal isolates and a marked decrease in the viable counts of most enterococcal strains (from 0.2 to 2.5 log(10) CFU/ml). Unlike vancomycin, which demonstrates time-dependent killing, AC98-6446 demonstrated concentration-dependent killing. The potent activity, novel structure, and bactericidal activity demonstrated by AC98-6446 make it an attractive candidate for further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.